Warburg leads PE flow into Indian APIs with Laurus investment
This article was originally published in Scrip
Niche active pharmaceutical ingredient (API) players in India continue to attract private equity interest - the latest deal involving Warburg Pincus' acquisition of a minority stake in Laurus Labs for about INR5.50bn ($92m).
You may also be interested in...
Niche therapy players, backed by strong technology platforms, continue to attract rich valuations in India, the latest being the Singapore-based private equity firm Quadria Capital's investment in Concord Biotech Ltd, an Indian manufacturer of fermentation based biopharmaceutical APIs [active pharmaceutical ingredients].
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.